A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Latest Information Update: 05 Feb 2026
At a glance
- Drugs Catequentinib (Primary) ; Bevacizumab; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 30 Jan 2026 Planned End Date changed from 31 Dec 2025 to 1 Dec 2026.
- 30 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.